Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)
South Korea
· Delayed Price · Currency is KRW 8,820.00
-90.00 (-1.01%)
Jun 27, 2025, 3:30 PM KST
Hyundai Bioscience Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 10,709 | 15,050 | 9,481 | 7,852 | 9,241 | 12,511 | Upgrade
|
Other Revenue | -0 | -0 | -0 | - | - | - | Upgrade
|
| 10,709 | 15,050 | 9,481 | 7,852 | 9,241 | 12,511 | Upgrade
| |
Revenue Growth (YoY) | -5.80% | 58.73% | 20.76% | -15.04% | -26.14% | -58.41% | Upgrade
|
Cost of Revenue | 1,520 | 3,258 | 4,490 | 5,140 | 6,012 | 6,104 | Upgrade
|
Gross Profit | 9,189 | 11,792 | 4,992 | 2,712 | 3,229 | 6,408 | Upgrade
|
Selling, General & Admin | 8,439 | 7,640 | 7,846 | 6,542 | 6,647 | 6,283 | Upgrade
|
Research & Development | 5,062 | 3,055 | 6,401 | 16,456 | 4,763 | 1,968 | Upgrade
|
Other Operating Expenses | 42.44 | 38.4 | 42.25 | 27.37 | 61.28 | 40.98 | Upgrade
|
Operating Expenses | 13,901 | 11,001 | 14,795 | 29,023 | 12,519 | 10,838 | Upgrade
|
Operating Income | -4,712 | 790.97 | -9,804 | -26,311 | -9,289 | -4,430 | Upgrade
|
Interest Expense | -2,313 | -2,313 | -314.57 | -448.65 | -3,003 | -1,130 | Upgrade
|
Interest & Investment Income | 562.35 | 210.7 | 669.19 | 536.69 | 291.71 | 195.91 | Upgrade
|
Earnings From Equity Investments | -6,877 | -5,730 | - | 8,834 | 93.91 | 1,542 | Upgrade
|
Currency Exchange Gain (Loss) | 23.32 | 3.73 | -68.67 | 48.15 | 20.39 | -102.31 | Upgrade
|
Other Non Operating Income (Expenses) | -948.29 | 94.13 | -335.47 | -182.82 | -404.46 | -1,179 | Upgrade
|
EBT Excluding Unusual Items | -14,265 | -6,944 | -9,853 | -17,524 | -12,291 | -5,104 | Upgrade
|
Gain (Loss) on Sale of Investments | 14.05 | 14.05 | 123.67 | 910.99 | - | - | Upgrade
|
Asset Writedown | - | - | -4,769 | - | -7,517 | -2,829 | Upgrade
|
Pretax Income | -14,251 | -6,930 | -14,498 | -16,613 | -19,808 | -7,933 | Upgrade
|
Income Tax Expense | 2.81 | - | 1.04 | -805.47 | 243.5 | 326.46 | Upgrade
|
Earnings From Continuing Operations | -14,253 | -6,930 | -14,499 | -15,807 | -20,051 | -8,260 | Upgrade
|
Net Income | -14,253 | -6,930 | -14,499 | -15,807 | -20,051 | -8,260 | Upgrade
|
Net Income to Common | -14,253 | -6,930 | -14,499 | -15,807 | -20,051 | -8,260 | Upgrade
|
Shares Outstanding (Basic) | 41 | 40 | 40 | 39 | 37 | 36 | Upgrade
|
Shares Outstanding (Diluted) | 41 | 40 | 40 | 39 | 37 | 36 | Upgrade
|
Shares Change (YoY) | 2.61% | 0.10% | 1.04% | 6.64% | 2.79% | 3.67% | Upgrade
|
EPS (Basic) | -348.97 | -174.03 | -364.53 | -401.53 | -543.16 | -229.99 | Upgrade
|
EPS (Diluted) | -349.41 | -174.03 | -365.00 | -402.00 | -543.16 | -230.00 | Upgrade
|
Free Cash Flow | 5,654 | 2,087 | -6,548 | -18,087 | -4,285 | -17,702 | Upgrade
|
Free Cash Flow Per Share | 138.43 | 52.43 | -164.62 | -459.44 | -116.08 | -492.91 | Upgrade
|
Gross Margin | 85.80% | 78.35% | 52.65% | 34.53% | 34.95% | 51.22% | Upgrade
|
Operating Margin | -44.00% | 5.26% | -103.40% | -335.10% | -100.52% | -35.41% | Upgrade
|
Profit Margin | -133.10% | -46.04% | -152.92% | -201.33% | -216.97% | -66.02% | Upgrade
|
Free Cash Flow Margin | 52.80% | 13.87% | -69.06% | -230.36% | -46.37% | -141.49% | Upgrade
|
EBITDA | -3,937 | 1,425 | -8,369 | -24,529 | -6,586 | -652.3 | Upgrade
|
EBITDA Margin | -36.76% | 9.47% | -88.27% | - | -71.27% | -5.21% | Upgrade
|
D&A For EBITDA | 775.37 | 633.82 | 1,435 | 1,782 | 2,703 | 3,778 | Upgrade
|
EBIT | -4,712 | 790.97 | -9,804 | -26,311 | -9,289 | -4,430 | Upgrade
|
EBIT Margin | -44.00% | 5.26% | -103.40% | - | -100.52% | -35.41% | Upgrade
|
Advertising Expenses | - | 267.64 | 996.63 | 965.59 | 1,497 | 798.47 | Upgrade
|
Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.